You need to enable JavaScript to run this app.
Researchers Question Consistency of FDA’s Use of Surrogate Endpoints for Drug Approvals
Regulatory News
Zachary Brennan
Regulatory NewsZachary Brennan
Regulatory NewsZachary Brennan